secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verastem, Inc. (VSTM)
CIK:        0001526119
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001104659-25-055322
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verastem reports 83% ORR in RAMP 205 PDAC trial; details VS-7375 KRAS G12D inhibitor
--------------------------------------------------------------------------------

- FDA approved avutometinib + defactinib (AVMAPKI/FAKZYNJA) on May 8, 2025 for KRAS-mutated recurrent LGSOC.
- RAMP 205 Phase 1/2 in first-line mPDAC: 83% unconfirmed ORR (10/12) at dose level 1; all patients had tumor shrinkage.
- RP2D set: avutometinib 2.4mg, defactinib 200mg, gemcitabine 800mg/m2, nab-paclitaxel 125mg/m2.
- VS-7375: oral KRAS G12D ON/OFF inhibitor with potent preclinical selectivity and activity; Phase 1/2a trial planned.
- Preliminary data suggest patients may exceed historical median PFS for gemcitabine/nab-paclitaxel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1526119/000110465925055322/0001104659-25-055322-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1526119/000110465925055322/tm2516844d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-055322

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer